Abstract
Background The healthcare industry is undergoing rapid transformation and progress, fueled by technological advances and the growing need for accessible, affordable, and high-quality healthcare services. While there has been significant progress in digitizing healthcare, especially during the COVID-19 pandemic, there is still considerable untapped potential for digital therapeutics (DTx). According to a report by Bloomberg, the digital health market is projected to reach $1.5 trillion by 2030 (1). However, most ventures in the space struggle to gain traction and eventually stop operations. Also, the diverse regulatory guidelines across countries challenge the scalability of DTx.
Objective The protocol described here outlines the methodology for a systematic review which’s objective is to identify factors that contribute to the successful scaling of digital health companies that have a validated product or service, i.e., growth-stage companies. A further objective is to highlight the key metrics used to quantify success in digital health companies.
Method We will search business and scientific databases, including EBSCO, PubMed, ProQuest, and Scopus, summarize the key findings and highlight the specific success factors relevant to the Digital Health Technologies (DHT) industry. The quality of the selected studies will be assessed using the critical appraisal skills program (CASP) checklists.
Expected outcome The literature review’s primary objective is to identify essential characteristics and recurring patterns that significantly contribute to success among growth-stage digital health companies. It will bridge the existing knowledge gap and provide stakeholders, including investors and entrepreneurs, with a valuable resource that supports informed decision-making and enhances the success of growth-stage digital health companies.
OSF Registration https://doi.org/10.17605/OSF.IO/UYJCA
Competing Interest Statement
EP, LB, MN, and TK are affiliated with the Centre for Digital Health Interventions (CDHI), a joint initiative of the Institute for Implementation Science in Health Care, University of Zurich, the Department of Management, Technology, and Economics at ETH Zurich, and the Institute of Technology Management and School of Medicine at the University of St. Gallen. CDHI is funded in part by CSS, a Swiss health insurer, the Swiss growth-stage investor MTIP, and the Austrian health provider Mavie Next. TK is also a co-founder of Pathmate Technologies, a university spin-off company that creates and delivers digital clinical pathways. However, this research did not involve CSS, Mavie Next, or Pathmate Technologies. EP and CK work at MTIP, a Swiss healthtech growth equity firm that helps founders scale up successful and sustainable digital health businesses.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript
